Måndag 27 April | 04:30:27 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-05 18:30 Kvartalsrapport 2026-Q3
2026-08-20 18:30 Kvartalsrapport 2026-Q2
2026-05-08 N/A X-dag ordinarie utdelning MCLR 0.00 SEK
2026-05-07 18:30 Kvartalsrapport 2026-Q1
2026-02-19 - Bokslutskommuniké 2025
2025-11-06 - Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-09 - X-dag ordinarie utdelning MCLR 0.00 SEK
2025-05-08 - Kvartalsrapport 2025-Q1
2025-04-16 - Årsstämma
2025-02-28 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-09 - Kvartalsrapport 2024-Q2
2024-05-14 - Kvartalsrapport 2024-Q1
2024-04-19 - X-dag ordinarie utdelning MCLR 0.00 SEK
2024-04-18 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - X-dag ordinarie utdelning MCLR 0.00 SEK
2023-05-11 - Årsstämma
2023-05-10 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-11 - Kvartalsrapport 2022-Q2
2022-05-05 - Kvartalsrapport 2022-Q1
2022-04-07 - X-dag ordinarie utdelning MCLR 0.00 SEK
2022-04-06 - Årsstämma
2022-02-23 - Bokslutskommuniké 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-06-02 - X-dag ordinarie utdelning MCLR 0.00 SEK
2021-03-03 - Extra Bolagsstämma 2021
2021-02-23 - Bokslutskommuniké 2020
2020-08-19 - Kvartalsrapport 2020-Q2
2020-06-11 - X-dag ordinarie utdelning MCLR 0.00 SEK
2020-06-10 - Årsstämma
2020-02-21 - Bokslutskommuniké 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-22 - X-dag ordinarie utdelning MCLR 0.00 SEK
2019-05-21 - Årsstämma
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning MCLR 0.00 SEK
2018-05-16 - Årsstämma
2018-02-16 - Bokslutskommuniké 2017
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-19 - X-dag ordinarie utdelning MCLR 0.00 SEK
2017-05-18 - Årsstämma

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHandel & varor
IndustriSällanköpsvaror
Medclair är ett svenskt cleantech-bolag som utvecklar teknik för hållbar hantering av lustgas inom sjukvård, återvinningsindustri och andra branscher med lustgasanvändning. Bolaget har en etablerad internationell närvaro och erbjuder lösningar som ämnar till att både minska klimatpåverkan och förbättra arbetsmiljön. Huvudkontoret ligger i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-04-22 18:05:00

The Annual General Meeting of Medclair was held in Stockholm on April 22, 2026. A summary of the resolutions follows below.

Resolution on the adoption of accounts and appropriation of profit
The meeting adopted the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet and resolved, in accordance with the proposal of the Board of Directors and the CEO, that the year's results be appropriated according to the Board's proposal in the annual report.

Discharge from liability
The meeting granted the members of the Board of Directors and the CEO discharge from liability for the 2025 financial year.

Election and remuneration of the Board and auditor
Fredrik Crafoord, Mark Baljeu, Jens Johansson, and Martin Roos were elected to the Board. Fredrik Crafoord was elected as Chairman. Allians Revision & Redovisning was elected as auditor, with Sofia Gunnarsson as the auditor in charge. The meeting resolved that Board fees shall be paid in the amount of SEK 220,000 to the Chairman of the Board and SEK 140,000 to each of the Board members. The auditor shall be remunerated according to approved invoices.

Resolution on authorization for the Board to resolve on issues
The meeting resolved to authorize the Board, during the period until the next Annual General Meeting, on one or more occasions and with or without deviation from the shareholders' preferential rights, to resolve on the new issue of shares, convertibles, and/or warrants. Payment may be made in cash, in kind, by set-off, or otherwise be associated with conditions.

The company's share capital and the number of shares may, with the support of the authorization, be increased by a total maximum amount and number, respectively, that fall within the limits of the articles of association. Deviation from the shareholders' preferential rights shall be permitted in order to strengthen the company's financial position if necessary and to enable the acquisition of companies or businesses. In the event of deviation from the shareholders' preferential rights and in the case of payment in kind or by set-off, the issue price shall correspond to the market value of the share with—where applicable—a market-based issue discount.